BR112022020418A2 - Compostos e métodos para modulação de splicing - Google Patents

Compostos e métodos para modulação de splicing

Info

Publication number
BR112022020418A2
BR112022020418A2 BR112022020418A BR112022020418A BR112022020418A2 BR 112022020418 A2 BR112022020418 A2 BR 112022020418A2 BR 112022020418 A BR112022020418 A BR 112022020418A BR 112022020418 A BR112022020418 A BR 112022020418A BR 112022020418 A2 BR112022020418 A2 BR 112022020418A2
Authority
BR
Brazil
Prior art keywords
compounds
methods
splicing
splicing modulation
modulation
Prior art date
Application number
BR112022020418A
Other languages
English (en)
Portuguese (pt)
Inventor
Reynolds Dominic
W Seiler Michael
A Agrawal Anant
Vaillancourt Frederic
Smith Peter
Leger Serge
Original Assignee
Remix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remix Therapeutics Inc filed Critical Remix Therapeutics Inc
Publication of BR112022020418A2 publication Critical patent/BR112022020418A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Replacement Of Web Rolls (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
BR112022020418A 2020-04-08 2021-04-08 Compostos e métodos para modulação de splicing BR112022020418A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063007327P 2020-04-08 2020-04-08
US202063043920P 2020-06-25 2020-06-25
US202063072873P 2020-08-31 2020-08-31
US202063126493P 2020-12-16 2020-12-16
PCT/US2021/026435 WO2021207530A1 (en) 2020-04-08 2021-04-08 Compounds and methods for modulating splicing

Publications (1)

Publication Number Publication Date
BR112022020418A2 true BR112022020418A2 (pt) 2023-05-02

Family

ID=75747105

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022020418A BR112022020418A2 (pt) 2020-04-08 2021-04-08 Compostos e métodos para modulação de splicing
BR112022020337A BR112022020337A2 (pt) 2020-04-08 2021-04-08 Compostos e métodos para modulação de splicing

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022020337A BR112022020337A2 (pt) 2020-04-08 2021-04-08 Compostos e métodos para modulação de splicing

Country Status (14)

Country Link
US (2) US20240287097A1 (enExample)
EP (2) EP4132936A1 (enExample)
JP (2) JP7797407B2 (enExample)
KR (2) KR20230004575A (enExample)
CN (2) CN116096725A (enExample)
AU (2) AU2021251220A1 (enExample)
BR (2) BR112022020418A2 (enExample)
CA (2) CA3175205A1 (enExample)
CL (1) CL2022002779A1 (enExample)
CO (1) CO2022015926A2 (enExample)
CR (1) CR20220567A (enExample)
IL (1) IL297149A (enExample)
MX (2) MX2022012677A (enExample)
WO (2) WO2021207550A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163541A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603594B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
WO2021231571A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
EP4308577B1 (en) * 2021-03-17 2024-12-25 F. Hoffmann-La Roche AG New thiadiazolopyrimidone derivatives
CR20230437A (es) * 2021-03-17 2023-10-16 Hoffmann La Roche Nuevos derivados de tiazolopirimidinona
EP4308572B1 (en) * 2021-03-17 2025-04-23 F. Hoffmann-La Roche AG New thienopyrimidinone derivatives
TW202330552A (zh) * 2021-10-13 2023-08-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
AU2022394333A1 (en) 2021-11-17 2024-06-27 Chdi Foundation, Inc. HTT modulators for treating Huntington’s disease
JP2024541481A (ja) * 2021-11-24 2024-11-08 リミックス セラピューティクス インコーポレイテッド スプライシングを調整するための化合物及び方法
CN115112899B (zh) * 2022-06-15 2024-08-16 四川大学华西医院 检测羧肽酶a4的试剂和/或系统在制备恶性胸腔积液筛查产品中的用途
CN121653249B (zh) * 2026-02-09 2026-05-26 中国医学科学院医学生物学研究所 Dnal1基因作为靶点在筛选防治寨卡病毒或2型登革病毒感染药物中的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB242502A (en) * 1925-03-10 1925-11-12 Hoe & Co R Improvements in stapling and folding mechanism
JPS57142989A (en) * 1981-02-27 1982-09-03 Dai Ichi Seiyaku Co Ltd Thiazolopyrimidine derivative
JPS58177997A (ja) * 1982-04-12 1983-10-18 Dai Ichi Seiyaku Co Ltd チアジアゾロピリミジノン誘導体
ES2016293B3 (es) * 1986-03-19 1990-11-01 Kumiai Chemical Industry Co Fungicida agricola-horticola.
TW449600B (en) * 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
US6153614A (en) 1998-07-16 2000-11-28 Abbott Laboratories Piperazinyl pyrimidine dione compounds selective for adrenoceptors
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US20060194871A1 (en) 2003-04-11 2006-08-31 Barvian Kevin K Heterocyclic mchr1 antagoists
WO2005047293A1 (en) * 2003-11-07 2005-05-26 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
KR100846988B1 (ko) 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
WO2008057601A2 (en) * 2006-11-08 2008-05-15 The Rockefeller University Organic compounds
EP2593106A4 (en) 2010-07-16 2014-01-01 Univ Rockefeller ORGANIC CONNECTIONS
JP2014519519A (ja) 2011-06-15 2014-08-14 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規3,4,4a,10b−テトラヒドロ−1H−チオピラノ[4,3−c]イソキノリン化合物
US20130102601A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2013109632A2 (en) 2012-01-16 2013-07-25 The Rockefeller University Organic compounds
EP3406252B1 (en) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
TWI693227B (zh) * 2014-04-23 2020-05-11 日商田邊三菱製藥股份有限公司 新穎二環性或三環性雜環化合物
AU2015261046C1 (en) 2014-05-15 2019-07-25 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
WO2015185531A1 (de) 2014-06-05 2015-12-10 Bayer Cropscience Aktiengesellschaft Bicyclische verbindungen als schädlingsbekämpfungsmittel
EP3256126B1 (en) 2015-02-09 2024-03-27 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
CN106279211B (zh) 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
JP6791717B2 (ja) * 2015-10-22 2020-11-25 田辺三菱製薬株式会社 医薬組成物
AR106472A1 (es) * 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
SG11201902588PA (en) * 2016-09-23 2019-05-30 Bayer Ag N3-Cyclically Substituted Thienouracils And Use Thereof
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
KR102736865B1 (ko) * 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
US20230152257A1 (en) 2017-09-25 2023-05-18 Skyhawk Therapeutics, Inc. Methods and compositions for screening and identification of splicing
US10584133B2 (en) 2018-03-30 2020-03-10 Biotheryx, Inc. Thienopyrimidinone compounds
JP2021521200A (ja) 2018-04-10 2021-08-26 スカイホーク・セラピューティクス・インコーポレーテッド 癌の処置のための化合物
WO2020004594A1 (ja) * 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
CR20230437A (es) * 2021-03-17 2023-10-16 Hoffmann La Roche Nuevos derivados de tiazolopirimidinona
EP4308577B1 (en) * 2021-03-17 2024-12-25 F. Hoffmann-La Roche AG New thiadiazolopyrimidone derivatives

Also Published As

Publication number Publication date
IL297149A (en) 2022-12-01
EP4132936A1 (en) 2023-02-15
BR112022020337A2 (pt) 2022-12-13
US20240279239A1 (en) 2024-08-22
WO2021207530A8 (en) 2021-12-02
KR20230005210A (ko) 2023-01-09
EP4132935A1 (en) 2023-02-15
MX2022012676A (es) 2023-01-11
CL2022002779A1 (es) 2023-04-28
US20240287097A1 (en) 2024-08-29
CA3175193A1 (en) 2021-10-14
CN116096725A (zh) 2023-05-09
AU2021251220A1 (en) 2022-11-03
WO2021207550A1 (en) 2021-10-14
JP7882782B2 (ja) 2026-06-30
AU2021253571A1 (en) 2022-11-10
WO2021207530A1 (en) 2021-10-14
JP2023520924A (ja) 2023-05-22
MX2022012677A (es) 2023-01-11
CO2022015926A2 (es) 2022-11-29
CR20220567A (es) 2023-01-13
JP2023520925A (ja) 2023-05-22
CA3175205A1 (en) 2021-10-14
CN116134036A (zh) 2023-05-16
JP7797407B2 (ja) 2026-01-13
KR20230004575A (ko) 2023-01-06

Similar Documents

Publication Publication Date Title
BR112022017210A2 (pt) Compostos e métodos para modulação de splicing
BR112022020423A2 (pt) Compostos e métodos para modulação de splicing
BR112022020337A2 (pt) Compostos e métodos para modulação de splicing
BR112022017107A2 (pt) Derivados de piridazina para modulação de splicing de ácido nucleico
CL2021003373A1 (es) Nuevos inhibidores de egfr
MX2022010681A (es) Compuestos y metodos para modular el empalme.
CL2020000937A1 (es) Anticuerpo multiespecífico.
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
CL2024000558A1 (es) Malonamidas herbicidas
AR131685A1 (es) 1h-pirazol-4-carboxamidas sustituidas como inhibidores de sarm1
CL2024000632A1 (es) Compuestos y métodos para modular el empalme
CO2024002648A2 (es) Compuestos y métodos para modular splicing
CO2025017487A2 (es) Compuestos y métodos para modular el empalme
CR20220483A (es) Compuestos y métodos para modular el empalme
PE20221571A1 (es) Metodo de marcaje de un hidrocarburo de petroleo
DOP2020000226A (es) Método para marcar un hidrocarburo de petróleo
BR112017016350A2 (pt) molécula de substrato

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: VIDE PARECER.

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]